Although the mechanistic basis for this relationship remains unknown, variation in tumor 24-hydroxylase levels may contribute to a differential benefit of vitamin D supplementation in patients with KRAS-mutant and EGFR-mutant tumors. This evidence concerns the gene EGFR and neoplasm.